NCT06715280RecruitingPhase 4
Switching of Sildenafil to Riociguat in CTEPH Patients
Switching Sildenafil to Riociguat in Chronic Thromboembolic Pulmonary Hypertension After Balloon Pulmonary Angioplasty
Source: ClinicalTrials.gov · Last updated 29 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study was designed to investigate the safety and efficacy of replacing phosphodiesterase 5 inhibitors (PDE5i) with riociguat in patients with Chronic thromboembolic pulmonary hypertension (CTEPH) who have undergone pulmonary angioplasty (BPA) and remains symptomatic despite treatments with PDE5i.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 26 Nov 2024
- Start date
- 25 Jul 2024
- Primary completion date
- 22 Jul 2026
- Lead sponsor
- Chinese University of Hong Kong
- NCT number
- NCT06715280
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 30
- From 25 Jul 2024 to the primary completion date, 22 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment with riociguat other sGCs, or documented severe drug reaction or intolerance to sGCs
Other illness
- Renal impairment with glomerular filtration rate \<15mL /min
- Child-Pugh C hepatic impairment
Other
- Use of nitrates or nitric oxide donors (eg, nitroglycerin, amyl nitrite, isosorbide dinitrate etc) by any administration routes within 30 days of screening
- Pregnant women or breast-feeding women, or women with childbearing potential not using of combination of two effective contraception methods throughout study
Who the study is looking for
- Patients with established diagnosis of CTEPH who are symptomatic after Balloon pulmonary angioplasty (BPA)
- Patients who are on stable maximally tolerated dose of sildenafil for at least 6 weeks as monotherapy, or in combination with other pulmonary hypertension specific therapies
- WHO functional class III at screening
- Stable dose of diuretics (if used) for at least 30 days at screening
- No recent hospitalisation due to pulmonary hypertension or heart failure for at least 30 days
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Prince of Wales Hospital Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.